811 related articles for article (PubMed ID: 19080989)
1. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
Puig L
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
[TBL] [Abstract][Full Text] [Related]
2. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
[TBL] [Abstract][Full Text] [Related]
3. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort.
Dalaker M; Bonesrønning JH
J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):277-82. PubMed ID: 19207642
[TBL] [Abstract][Full Text] [Related]
4. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
[TBL] [Abstract][Full Text] [Related]
5. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
Antoniou C; Stefanaki I; Stratigos A; Moustou E; Vergou T; Stavropoulos P; Avgerinou G; Rigopoulos D; Katsambas AD
Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of infliximab for severe recalcitrant psoriasis after 6 weeks of treatment.
DE Oliveira JP; Levy A; Morel P; Guibal F
J Dermatol; 2008 Sep; 35(9):575-80. PubMed ID: 18837702
[TBL] [Abstract][Full Text] [Related]
7. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
Menter A; Feldman SR; Weinstein GD; Papp K; Evans R; Guzzo C; Li S; Dooley LT; Arnold C; Gottlieb AB
J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
[TBL] [Abstract][Full Text] [Related]
9. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
Torii H; Nakagawa H;
J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
[TBL] [Abstract][Full Text] [Related]
10. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
11. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
[TBL] [Abstract][Full Text] [Related]
12. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo.
Kalb RE; Gurske J
J Am Acad Dermatol; 2005 Oct; 53(4):616-22. PubMed ID: 16198781
[TBL] [Abstract][Full Text] [Related]
13. Initial experience with routine administration of etanercept in psoriasis.
de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
[TBL] [Abstract][Full Text] [Related]
14. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.
Kamili QU; Miner A; Hapa A; Menter A
J Drugs Dermatol; 2011 May; 10(5):539-44. PubMed ID: 21533302
[TBL] [Abstract][Full Text] [Related]
15. Treatment of severe psoriasis with infliximab: report of two cases.
Peternel S; Prpić-Massari L; Guina T; Novak S; Brajac I; Kastelan M
Acta Dermatovenerol Croat; 2009; 17(3):204-6. PubMed ID: 19818221
[TBL] [Abstract][Full Text] [Related]
16. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.
Wee JS; Petrof G; Jackson K; Barker JN; Smith CH
Br J Dermatol; 2012 Aug; 167(2):411-6. PubMed ID: 22404545
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
18. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India.
Kaur I; Dogra S; De D; Kanwar AJ
Pediatr Dermatol; 2008; 25(2):184-8. PubMed ID: 18429775
[TBL] [Abstract][Full Text] [Related]
19. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
Gottlieb AB; Evans R; Li S; Dooley LT; Guzzo CA; Baker D; Bala M; Marano CW; Menter A
J Am Acad Dermatol; 2004 Oct; 51(4):534-42. PubMed ID: 15389187
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
